Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism Lp-PLA2 inhibitors(Lipoprotein-associated phospholipase A2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Community Acquired Pneumonia | Phase 2 | China | 09 Sep 2024 | |
| Neuroinflammation | Phase 2 | China | 18 Nov 2022 | |
| Diabetic Nephropathies | Phase 2 | - | - | |
| Diabetic macular oedema | Phase 1 | China | 30 Jan 2022 | |
| Alzheimer Disease | Phase 1 | - | - | |
| Chronic Kidney Diseases | IND Approval | China | 03 Mar 2025 |





